MX2022012628A - Anticuerpos anti-phf-tau y usos de estos. - Google Patents

Anticuerpos anti-phf-tau y usos de estos.

Info

Publication number
MX2022012628A
MX2022012628A MX2022012628A MX2022012628A MX2022012628A MX 2022012628 A MX2022012628 A MX 2022012628A MX 2022012628 A MX2022012628 A MX 2022012628A MX 2022012628 A MX2022012628 A MX 2022012628A MX 2022012628 A MX2022012628 A MX 2022012628A
Authority
MX
Mexico
Prior art keywords
antibodies
phf
tau antibodies
tau
tauopathies
Prior art date
Application number
MX2022012628A
Other languages
English (en)
Inventor
Sanjaya Singh
Jinquan Luo
Rajkumar Ganesan
Marc Mercken
Kolen Kristof Van
Sathyadevi Venkataramani
Rupesh Nanjunda
Porte Sherry La
Pharavee Jaiprasart
Original Assignee
Janssen Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Biotech Inc filed Critical Janssen Biotech Inc
Publication of MX2022012628A publication Critical patent/MX2022012628A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurosurgery (AREA)
  • Medicinal Chemistry (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Plant Pathology (AREA)

Abstract

Se describen anticuerpos monoclonales anti-PHF-tau y fragmentos de unión al antígeno de estos. Además, se describen ácidos nucleicos que codifican los anticuerpos, composiciones que comprenden los anticuerpos, métodos para producir los anticuerpos y usar los anticuerpos para tratar o prevenir afecciones, tales como tauopatías.
MX2022012628A 2020-04-08 2021-04-07 Anticuerpos anti-phf-tau y usos de estos. MX2022012628A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063007118P 2020-04-08 2020-04-08
US202063026387P 2020-05-18 2020-05-18
PCT/IB2021/052890 WO2021205359A1 (en) 2020-04-08 2021-04-07 Anti-phf-tau antibodies and uses thereof

Publications (1)

Publication Number Publication Date
MX2022012628A true MX2022012628A (es) 2023-01-11

Family

ID=78023121

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022012628A MX2022012628A (es) 2020-04-08 2021-04-07 Anticuerpos anti-phf-tau y usos de estos.

Country Status (18)

Country Link
US (1) US20230151083A1 (es)
EP (1) EP4132569A4 (es)
JP (1) JP2023521763A (es)
KR (1) KR20220166308A (es)
CN (1) CN115697393A (es)
AU (1) AU2021251486A1 (es)
BR (1) BR112022020410A2 (es)
CA (1) CA3179914A1 (es)
CL (1) CL2022002766A1 (es)
CO (1) CO2022015737A2 (es)
CR (1) CR20220505A (es)
DO (1) DOP2022000218A (es)
EC (1) ECSP22078815A (es)
IL (1) IL297231A (es)
MX (1) MX2022012628A (es)
PE (1) PE20230385A1 (es)
TW (1) TW202204402A (es)
WO (1) WO2021205359A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023092004A1 (en) 2021-11-17 2023-05-25 Voyager Therapeutics, Inc. Compositions and methods for the treatment of tau-related disorders
TW202345899A (zh) * 2022-03-11 2023-12-01 比利時商健生藥品公司 多特異性抗體及其用途(三)
WO2023170290A1 (en) * 2022-03-11 2023-09-14 Janssen Pharmaceutica Nv Multispecific antibodies and uses thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3234629A1 (en) * 2011-12-20 2013-06-27 Janssen Biotech, Inc. Anti-phf-tau antibodies and their uses
WO2016112078A2 (en) * 2015-01-08 2016-07-14 Janssen Biotech, Inc. Anti-phf-tau antibodies and their uses
TN2017000543A1 (en) * 2015-07-06 2019-04-12 Ucb Biopharma Sprl Tau-binding antibodies
CN106939047B (zh) * 2016-01-04 2021-08-31 江苏怀瑜药业有限公司 一种pd-l1抗体及其制备方法
JOP20180021A1 (ar) * 2017-03-16 2019-01-30 Janssen Biotech Inc الأجسام المضادة لتكتلات خيوط بروتين تاو (tau) الحلزونية المزدوجة واستخداماتها

Also Published As

Publication number Publication date
EP4132569A1 (en) 2023-02-15
IL297231A (en) 2022-12-01
CL2022002766A1 (es) 2023-04-21
AU2021251486A1 (en) 2022-12-08
DOP2022000218A (es) 2023-04-30
TW202204402A (zh) 2022-02-01
CN115697393A (zh) 2023-02-03
CR20220505A (es) 2023-05-31
CA3179914A1 (en) 2021-10-14
BR112022020410A2 (pt) 2023-01-03
PE20230385A1 (es) 2023-03-06
EP4132569A4 (en) 2024-07-31
ECSP22078815A (es) 2022-11-30
KR20220166308A (ko) 2022-12-16
JP2023521763A (ja) 2023-05-25
CO2022015737A2 (es) 2023-02-27
US20230151083A1 (en) 2023-05-18
WO2021205359A1 (en) 2021-10-14

Similar Documents

Publication Publication Date Title
PH12019501973A1 (en) Anti-phf-tau antibodies and uses thereof
MX2020009366A (es) Anticuerpos anti-cd73 y usos de los mismos.
PH12020552010A1 (en) Anti-cd33 antibodies, anti-cd33/anti-cd3 bispecific antibodies and uses thereof
ZA202004730B (en) Anti-claudin 18.2 antibodies and uses thereof
CR20220505A (es) Anticuerpos anti-phf-tau y usos de estos
MX2020011914A (es) Anticuerpos anti-dll3 y usos de los mismos.
MX2020009522A (es) Anticuerpos anti-folato del receptor 1 y usos de los mismos.
WO2021212049A3 (en) Anti-sars-cov-2 monoclonal antibodies
MX2022010664A (es) Materiales y métodos para modular una respuesta inmunitaria.
MX2023011339A (es) Anticuerpos anti-tau y usos de estos.
PH12020551373A1 (en) Anti-phf-tau antibodies and uses thereof
MX2024002238A (es) Anticuerpos anti-ccr8 y uso de los mismos.
JOP20210297A1 (ar) مواد وطرق لحث المناعة التي تساهم فيها الخلايا التائية
MX2021004454A (es) Anticuerpos anti-sinucleina.
MX2023004869A (es) Anticuerpos contra sars-cov-2 y usos de los mismos.
MX2023014458A (es) Anticuerpos anti-ccr8 y usos de los mismos.
MX2023001776A (es) Anticuerpos contra ilt2 y uso de los mismos.
MX2023014154A (es) Anticuerpos anti-ccr8.
MX2022013920A (es) Anticuerpos anti-antigeno asociado con tumor y usos de los mismos.
MX2023002948A (es) Métodos y composiciones para modular la inmunidad mediada por cadena beta.
MX2022015966A (es) Anticuerpos y metodos para tratar enfermedades asociadas a claudina.
MX2023011340A (es) Anticuerpos humanizados contra el filamento helicoidal emparejado tau y usos de estos.
EA202092122A1 (ru) Антитела против tip-1 и их применения
AU2018345715A8 (en) DNA monoclonal antibodies targeting CTLA-4 for the treatment and prevention of cancer
MX2022007513A (es) Anticuerpos biespecificos con cisteinas intercatenarias apareadas alternativamente y sus usos.